Stockwinners Market Radar for September 12, 2023 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service

20:19 EDT Cathie Wood's ARK Investment bought 228K shares of Velo3D today

20:18 EDT Cathie Wood's ARK Investment bought 440K shares of Robinhood today

19:48 EDT Vitesse CEO buys $117.8K in common stock - In a regulatory filing, Vitesse disclosed that its CEO Robert Gerrity bought 5K shares of common stock on September 11th in a total transaction size of $117.8K. Shares of Vitesse are up 0.5% afterhours at $24.26.

18:28 EDT Lyft launches 'Women + Connect' feature - In a company blog post, Lyft announced a new feature called "Women + Connect" which prioritizes matches between women and nonbinary drivers and riders. Reference Link

18:24 EDT Lyft CEO: We're executing better every single day - In an interview on CNBC's Mad Money, David Risher said he expects the new "Women+Connect" feature will feed on itself and get bigger. "I believe this gives women a reason to choose Lyft," he noted. Commutes are up 19% y/y and he expects the trend to accelerate. "It's crazy there are only two players in this market," he added.

17:48 EDT Salesforce Chairman Benioff sells $3.4M in company shares - The Chairman of Salesforce Marc Benioff disclosed in a regulatory filing that he had sold 15,000 shares of company stock at $224.81 per share on September 11, for a total transaction amount of $3,372,081.

17:39 EDT Applied Optoelectronics terminates Prime World asset sale - In a regulatory 8-K filing, the company states: "Applied Optoelectronics previously reported in its Current Report on Form 8-K dated September 15, 2022 that the Company and Prime World International Holdings Ltd., which is a company incorporated in the British Virgin Islands and a wholly owned subsidiary of AOI, entered into a definitive agreement with Yuhan Optoelectronic Technology Co., Ltd. Pursuant to the Purchase Agreement, AOI agreed to sell its manufacturing facilities located in the People's Republic of China and certain assets related to its transceiver business and multi-channel optical sub-assembly products for the internet datacenter, fiber-to-the-home and telecom markets. On September 12, 2023, AOI and the Seller delivered a notice of termination to the Purchaser to terminate the Purchase Agreement as a result of the Purchaser's breach of or omission to observe certain of the Purchaser's obligations under the Purchase Agreement. As a result of the Company's delivery of the Termination Notice, the Purchase Agreement has been terminated."

17:17 EDT Lockheed Martin awarded $311.98M Army contract agreement - Lockheed Martin was awarded an Other Transaction Authority agreement with a ceiling of $311.98M for Stinger missile upgrades and replacement. Work will be performed in Grand Prairie, Texas, with an estimated completion date of June 12, 2028. FY23 research, development, test and evaluation, Army funds in the amount of $26.13M were obligated at the time of the award. Army Contracting Command is the contracting activity.

17:16 EDT RTX awarded $418.34M Army contract agreement - RTX was awarded an Other Transaction Authority agreement with a ceiling of $418.34M for Stinger missile upgrades and replacement. Work will be performed in Tucson, Arizona, with an estimated completion date of March 12, 2028. FY23 research, development, test and evaluation, Army funds in the amount of $26.13M were obligated at the time of the award. U.S. Army Contracting Command is the contracting activity.

17:10 EDT Lockheed Martin awarded $841.49M Navy contract modification - Lockheed Martin was awarded an $841.49M firm-fixed-price, cost-plus-incentive-fee modification to a previously awarded indefinite-delivery/indefinite-quantity contract. This modification exercises options to provide non-recurring site activation, initial sustainment and associated administrative support, to include fleet management, support equipment, pilot flight equipment, post ejection survival training material, program management, and earned value management in support of the F-35 Joint Strike Fighter program of the Air Force, Marine Corps, Navy, Foreign Military Sales customers, and non-Department of Defense participants. Work is expected to be completed in December 2029. No funds will be obligated at the time of award; funds will be obligated on individual orders as they are issued. Naval Air Systems Command is the contracting activity.

17:01 EDT Grainger appoints Matt Fortin as Chief Human Resources Officer - Grainger announced the appointment of Matt Fortin as Senior Vice President and Chief Human Resources Officer, effective Wednesday, September 13. With this appointment, he will join the Grainger Leadership Team. Matt joined Grainger in 2006 and most recently served as the Group Vice President for the Merchandising and Supplier Management function, leading the team responsible for building and publishing Grainger's product assortment. He has held roles of increasing responsibility across Grainger's supply chain and led the company's sourcing and commercial operations in China. Prior to joining Grainger, he spent 16 years at General Motors progressing through leadership roles in manufacturing, purchasing, continuous improvement and general management. Fortin graduated from the University of Dayton with a bachelor's degree in management information systems and graduated as a General Motors Fellow with an MBA from the Thunderbird School of Global Management.

16:50 EDT MorphoSys gets Tulmimetostat FDA fast track designation in endometrial cancer - MorphoSys "announced that the U.S. Food and Drug Administration granted Fast Track designation for tulmimetostat, the company's investigational next-generation dual inhibitor of EZH2 and EZH1, for the treatment of patients with advanced, recurrent or metastatic endometrial cancer harboring AT-rich interacting domain containing protein 1A (ARID1A) mutations and who have progressed on at least one prior line of treatment. The FDA grants Fast Track designation to facilitate the development and expedite the review of medicines intended to treat serious conditions and potentially address an unmet medical need, with the goal of getting these important, new therapies to patients earlier. Tulmimetostat was designed to improve on first generation EZH2 inhibitors through increased potency, longer residence time on target and a longer half-life, offering the potential for enhanced anti-tumor activity. The Fast Track designation in endometrial cancer was granted based on preclinical results and preliminary clinical data from an ongoing Phase 1/2 study. This study is investigating tulmimetostat as a monotherapy in patients with advanced solid tumors or lymphomas, including ARID1A-mutated endometrial carcinoma and ovarian clear cell carcinoma, diffuse large B-cell lymphoma, peripheral T-cell lymphoma, BAP1-mutated mesothelioma and castration-resistant prostate cancer. Updated results were presented at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting in June."

16:38 EDT Eiger BioPharmaceuticals down 27% at 51c per share after resumption of trade

16:35 EDT Eiger BioPharmaceuticals trading resumes

16:32 EDT Eiger BioPharmaceuticals to resume trading at 4:35 pm ET - Eiger BioPharmaceuticals shares are scheduled to resume trading at 4:35 pm ET, with quotation set to resume at 4:30 pm ET, according to Nasdaq. Eiger BioPharmaceuticals trading was halted, news pending, ahead of the company announcing that it is discontinuing Phase 3 LIMT-2 trial of peginterferon lambda in patients with chronic hepatitis delta.

16:22 EDT Rocket Pharmaceuticals jumps 31% after announcing FDA alignment on Ph.2 RP-A401

16:21 EDT AllianceBernstein reports preliminary AUM $694B as of August 31 - AllianceBernstein announced that preliminary assets under management decreased to $694B during August 2023 from $704B at the end of July. Positive net inflows across all three channels were offset by market depreciation, resulting in a 1.4% AUM decline during the month of August.

16:20 EDT Manchester United signs Qualcomm as shirt partner - Manchester United (MANU) has agreed to an expanded strategic collaboration with Qualcomm Technologies (QCOM) that will see the Snapdragon brand displayed on the front of the club's famous shirt. Qualcomm Technologies is already a global partner of Manchester United, promoting its Snapdragon brand. Snapdragon processors power premium products from the world's biggest brands across smartphones, PCs, extended reality glasses, gaming devices, wearables, and connected cars. Under the expanded agreement, Snapdragon will become Manchester United's front of shirt partner from the start of the 2024/25 season, featuring on the home, away and third kits of the men's and women's teams.

16:18 EDT Cooper Companies to transfer listing to Nasdaq from NYSE - Cooper Companies announced that it will transfer the listing of its common stock from the New York Stock Exchange to Nasdaq. Cooper expects to begin trading as a Nasdaq-listed company at market open on September 26 and will continue to trade under the symbol (COO).

16:16 EDT Invesco reports preliminary AUM $1.53T as of August 31 - Invesco reported preliminary month-end assets under management (AUM) of $1.53T, a decrease of 2.7% versus previous month-end. Net long-term flows were break even in the month.

16:13 EDT T-Mobile to acquire spectrum in 600 MHz band from Comcast for $1.2B-$3.3B - In a regulatory filing, T-Mobile (TMUS) states: "On September 12, 2023, T-Mobile US, Inc., its direct, wholly-owned subsidiary T-Mobile USA, Inc. and its affiliate T-Mobile License LLC , entered into a License Purchase Agreement with Comcast Corporation and its affiliate Comcast OTR1, LLC (CMCSA). Pursuant to the License Purchase Agreement, T-Mobile License LLC will acquire spectrum in the 600 MHz band from Comcas in exchange for total cash consideration of between $1.2 billion and $3.3 billion. Consummation of the proposed transactions is subject to various customary conditions, including, among others, expiration of the applicable waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended, and approval of the transaction by the Federal Communications Commission. The parties expect to make the requisite transfer filings with the FCC in the first half of 2027. The closing is anticipated by T-Mobile to occur in the first half of 2028. The License Purchase Agreement contains customary representations, warranties, and covenants. The final Purchase Price will be determined, in the aggregate and on a per License basis, based on the set of Licenses subject to the License Purchase Agreement at the time the parties make required transfer filings with the FCC. Prior to the time of such filings, Comcast has the right to remove any or all of a certain specified subset of the Licenses (the "Optional Sale Licenses") from the License Purchase Agreement. The removal of any Optional Sale Licenses would reduce from $3.3 billion the final Purchase Price by the assigned value of each such License. The Licenses are being acquired without any associated network, but the Licenses will be subject to a T-Mobile exclusive leasing arrangement entered into contemporaneously with the License Purchase Agreement. If Comcast elects to remove an Optional Sale License from the License Purchase Agreement, the associated lease for such Optional Sale License will terminate, but no sooner than two years from the date of the License Purchase Agreement. The geographic areas covered by the Licenses that may not be removed from the License Purchase Agreement include markets covering approximately 39 million pops, including New York, New York; Orlando, Florida; Kansas City, Missouri; and other markets. The geographic areas covered by the Optional Sale Licenses include markets covering approximately 110 million pops, including Chicago, Illinois; San Francisco, California; Baltimore, Maryland / Washington D.C.; Boston, Massachusetts; Miami, Florida; Nashville, Tennessee; and other markets. Each market's License covers 10MHz, except for Nashville, Tennessee, which covers 20MHz.

16:10 EDT Rocket Lab signs deal with Leidos to launch four HASTE missions - Rocket Lab USA (RKLB) announced it has signed a contract with Leidos (LDOS) to launch four HASTE (Hypersonic Accelerator Suborbital Test Electron) missions. The missions, scheduled across 2024 and 2025, will lift off from Rocket Lab Launch Complex 2 at Virginia's Mid-Atlantic Regional Spaceport within NASA's Wallops Flight Facility. Rocket Lab was selected by Leidos to provide hypersonic test launch capabilities with HASTE under the MACH-TB project. The project was awarded by Naval Surface Warfare Center (NSWC) Crane through the Strategic and Spectrum Missions Advanced Resilient Trusted Systems (S2MARTS) Other Transaction Authority (OTA) vehicle on behalf of the U.S. Department of Defense Test Resource Management Center (TRMC). "Our first HASTE mission in June this year successfully demonstrated HASTE's ability to accelerate the cadence of hypersonic flight testing for the nation. We're proud to now follow it up with a series of four additional missions for Leidos to support hypersonic technology innovation and technology maturation," said Brian Rogers, Senior Director - Global Launch Services.

16:09 EDT Workhorse Group gets IRS approval for Commercial Clean Vehicle Credit - Workhorse Group announced that it has received IRS approval as a qualified manufacturer for the Commercial Clean Vehicle Credit as defined in 30Dd3 of the Internal Revenue Code. With this approval, Workhorse customers are eligible to receive up to a $40,000 credit for deliveries of all Workhorse vehicles in 2023 and beyond. "We are focused on leading the transition to commercial EVs to make last-mile delivery more efficient and less harmful to the environment and are pleased that the IRS recognizes the inherent sustainability of our commercial EVs," said Workhorse CEO Rick Dauch. "We look forward to providing this credit to our customers as we deliver our all electric, dependable, high quality commercial vehicles." Workhorse will be listed as a Qualified Manufacturer on the IRS Qualified Manufactured index on IRS.gov.

16:07 EDT Virtus Investment reports August-end AUM of $169.4B vs. $171.9B last month - Virtus Investment Partners reported preliminary assets under management of $169.4 billion as of August 31, 2023. In addition, the company provided services to $2.6 billion of other fee-earning assets, which are not included in assets under management.

16:06 EDT Northern Star Investment Corp IV trading halted, news pending

16:05 EDT HireRight board authorizes additional $25M share repurchase program - HireRight Holdings announced its Board of Directors has authorized an additional $25M share repurchase program. Under the repurchase program, the company may purchase shares of its common stock on a discretionary basis from time to time through open market repurchases or privately negotiated transactions, or other means, including through Rule 10b5-1 trading plans. The timing and actual number of shares repurchased will depend on a variety of factors, including stock price, trading volume, market conditions and other general business considerations. The repurchase program may be modified, suspended, or terminated at any time.

16:02 EDT Rocket Pharmaceuticals reaches FDA alignment on Phase 2 RP-A401 trial design - Rocket Pharmaceuticals announced that alignment has been reached with the Food and Drug Administration on the global Phase 2 pivotal trial of RP-A501 for Danon Disease. Danon Disease is a uniformly fatal inherited cardiomyopathy that leads to mortality in the majority of male patients at age ~20 and females at age ~40, and for which there are no approved curative or disease-modifying therapies. The disease affects an estimated 15,000 to 30,000 patients in the U.S. and Europe. "I am very excited to announce our alignment with the FDA on our pivotal study design for RP-A501 for Danon Disease, which reflects the highly collaborative discussions with the review team and senior management at FDA's Center for Biologics Evaluation and Research and marks the first-ever regulatory pathway to approval for a genetic treatment for heart disease. We believe this milestone sets us on the most efficient and rapid path to delivering this potentially transformative therapy to Danon Disease patients who would otherwise progress to heart transplantation or death," said Gaurav Shah, M.D., Chief Executive Officer, Rocket Pharma. "I would also like to highlight the work conducted by our CMC team over the past several years to establish our in-house cGMP manufacturing capabilities, which has already provided us with sufficient material for the pivotal study and should support our eventual commercialization efforts."

16:01 EDT Eiger BioPharmaceuticals trading halted, news pending

15:13 EDT QuidelOrtho says shipped more product in Q3 than anticipated - Says more shipments "derisks" prior FY guidance. Says new shipment numbers support assertion that COVID is "just another respiratory virus" and is now "endemic." Says company should expect 2024 and beyond to see $200M-$400M in COVID specifically from COVID-only sales. Comments taken from Morgan Stanley Global Healthcare conference.

14:48 EDT BP confirms CEO Bernard Looney resigns with immediate effect

14:26 EDT Apple unveils Apple Watch Ultra 2 - Apple introduced Apple Watch Ultra 2, with new features and achieving "a significant environmental milestone," the company said. Apple Watch Ultra 2 offers all of the Ultra features, plus the new S9 SiP, a new double tap gesture, Apple's brightest display ever, expanded altitude range, on-device Siri, Precision Finding for iPhone, and advanced capabilities for water adventures. Apple Watch Ultra 2 runs watchOS 10, which delivers redesigned apps, the new Smart Stack, new cycling experiences, features to help explore the outdoors, and a new watch face - Modular Ultra. Apple Watch Ultra 2 has the same 36-hour battery life with regular use and up to 72 hours in Low Power Mode. For the first time, customers can choose a carbon neutral option of any Apple Watch, the company noted, "representing a significant milestone toward Apple 2030: Apple's plan to be carbon neutral across its entire business, manufacturing supply chain, and product life cycle by 2030." Apple Watch Ultra 2 can be ordered today, with availability beginning Friday, September 22.

14:24 EDT Apple introduces iPhone 15 Pro and iPhone 15 Pro Max - Apple debuted iPhone 15 Pro and iPhone 15 Pro Max, which it says are "designed with aerospace-grade titanium that's strong yet lightweight to deliver Apple's lightest Pro models ever." Apple says: "The new design also features contoured edges and a customizable Action button, allowing users to personalize their iPhone experience. Powerful camera upgrades enable the equivalent of seven pro lenses with incredible image quality, including a more advanced 48MP Main camera system that now supports the new super-high-resolution 24MP default, the next generation of portraits with Focus and Depth Control, improvements to Night mode and Smart HDR, and an all-new 5x Telephoto camera exclusively on iPhone 15 Pro Max. A17 Pro unlocks next-level gaming experiences and pro performance. The new USB-C connector is supercharged with USB 3 speeds - up to 20x faster than USB 2 - and together with new video formats, enables powerful pro workflows that were not possible before.1 And with the addition of Roadside Assistance via satellite, the iPhone 15 Pro lineup builds on Apple's innovative satellite infrastructure to connect users to help if they have car trouble while off the grid." iPhone 15 Pro and iPhone 15 Pro Max will be available in black titanium, white titanium, blue titanium, and natural titanium finishes. iPhone 15 Pro remains at the same starting price of $999 in the U.S. or $41.62 U.S. per month, available in 128GB, 256GB, 512GB, and 1TB storage capacities. iPhone 15 Pro Max starts at $1,199 in the U.S. or $49.95 U.S. per month , available in 256GB, 512GB, and 1TB storage capacities.

14:20 EDT Apple says all new iPhone 15s available September 22

14:09 EDT Apple says 'Resident Evil Village,' 'Resident Evil 4' playable on iPhone 15 pro - "Resident Evil" games are developed by Capcom (CCOEY), The Fly notes.

14:00 EDT Apple says iPhone 15 Pro comes with customizable action button - Says action button is still a simple ring/silent switch, but allows users to hold button to determine intent. Says button can switch easily button a number of different actions.

13:56 EDT Apple unveils iPhone 15 Pro, powered by most advanced Apple Silicon yet - Says 15 Pro delivers "most incredible" photos and videos.

13:51 EDT Apple says bringing USB-C to AirPods - Says iPhone 15 has MagSafe, which ensures alignment to different kinds of phone chargers.

13:46 EDT Apple says iPhone 15 comes with A16 procesesor

13:39 EDT Apple says iPhone 15 reaches peak HDR brightness up to 2,000 nits - Says iPhone 15 comes with OLED Super Retina XDR display. Says new phone comes with ceramic shield on screen.

13:36 EDT Apple unveils iPhone 15 with all-new design - Apple unveils iPhone 15 with all-new design

13:33 EDT Apple says Watch Ultra 2 has 36 hours of battery life on single charge - Says Ultra 2 has 72 hours of battery life on low power mode.

13:29 EDT Apple introduces Apple Watch Series 9 - Apple introduced Apple Watch Series 9, saying it is "bringing new features to the world's best-selling watch and achieving a significant environmental milestone." The company said: "Apple Watch Series 9 is more powerful than ever with the new S9 SiP, which increases performance and capabilities; a magical new double tap gesture; a brighter display; faster on-device Siri, now with the ability to access and log health data; Precision Finding for iPhone; and more. Apple Watch Series 9 runs watchOS 10, which delivers redesigned apps, the new Smart Stack, new watch faces, new cycling and hiking features, and tools to support mental health. For the first time, customers can choose a carbon neutral option of any Apple Watch, representing a significant milestone toward Apple 2030: Apple's plan to be carbon neutral across its entire business, manufacturing supply chain, and product life cycle by 2030." Customers in Australia, Canada, France, Germany, India, Japan, the UAE, the U.K., the U.S., and more than 40 other countries and regions can order Apple Watch Series 9 and Apple Watch SE today, with availability in stores beginning Friday, September 22. Apple Watch Series 9 starts at $399 in the U.S., and Apple Watch SE starts at $249 in the U.S.

13:23 EDT Fox News Media extends Baier's contract, to continue as chief political anchor - FOX News Media has extended Bret Baier's multi-year contract where he will continue his role as chief political anchor, and anchor and executive editor of Special Report, announced president and executive editor Jay Wallace. Additionally, Baier will continue to co-anchor 2024 election coverage and host The Bret Baier Podcast on FOX News Audio. In making the announcement, Wallace said, "We are thrilled to have Bret continue leading our political coverage as we head into the 2024 election season and beyond."

13:22 EDT Reata says waiting period related to merger under Hart-Scott-Rodino act expired - In a regulatory filing, Reata Pharmaceuticals (RETA) noted that, as previously disclosed on July 28, the company, Biogen (BIIB), and River Acquisition, a Delaware corporation and a wholly-owned subsidiary of Biogen, entered into an agreement and plan of merger, pursuant to which, and upon the terms and subject to the conditions set forth therein, merger sub will be merged with and into Reata, with Reata surviving the merger as a wholly-owned subsidiary of Biogen. "The applicable waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended, in connection with the merger expired at 11:59 p.m. Eastern Time on September 11, 2023. The consummation of the merger remains subject to other customary closing conditions specified in the merger agreement, including, among others, receipt of the affirmative vote of the holders of a majority of the voting power of the outstanding shares of Class A common stock, par value $0.001 per share, and the outstanding shares of Class B common stock, par value $0.001 per share, of Reata to adopt the merger agreement and approve the transactions contemplated thereby. As previously disclosed, a special meeting of the stockholders of Reata in connection with the proposed merger has been scheduled to be held virtually via live webcast at 8:00 a.m. Central Time on September 21," the filing stated.

13:17 EDT Apple Watch double tap feature available next month

13:15 EDT Apple says Watch sesries 9 comes with added tap motion controls - Says Watch users can double-tap their fingers while using the watch to answer calls, hang up calls, and utilize other features.

13:09 EDT Apple unveils next-generation Apple Watch Series 9 - Says still on track to ship Vision Pro in early 2024. Comments taken from September 12 Apple Event.

12:37 EDT Axolotl Biologix finalizes merger with Carmell Therapeutics - Moonshot announced that its incubator client, Axolotl Biologix, based in its NACET Flagstaff, Arizona campus, has finalized a merger with Carmell Therapeutics. As outlined in the Merger Agreement, Axolotl's shareholders will receive an Initial Equity Value of $65M, allocated as $8M in cash and $57M in CTCX stock upon closing. Additionally, they stand to gain up to $75M in potential Milestone Equity Payments, which are structured as 12% cash and 88% in CTCX stock, subject to the achievement of defined revenue and business benchmarks. "The merger between Carmell Therapeutics and Axolotl Biologix exemplifies the type of innovation and growth that Moonshot is designed to cultivate," stated Scott Hathcock, President & CEO of Moonshot. "Axolotl has been a standout client at our Flagstaff campus. This merger with an industry giant like Carmell Therapeutics is a significant development for the future of regenerative medicine."

12:03 EDT BAE Systems, L3Harris deliver first EC-37B aircraft to U.S. Air Force - BAE Systems (BAESY) and L3Harris Technologies (LHX) delivered the first of 10 EC-37B Compass Call aircraft to the U.S. Air Force for formal combined developmental and operational testing. "The delivery of the first EC-37B Compass Call is a major milestone for our customer's electromagnetic attack capabilities," said Dave Harrold, Vice President and General Manager, Countermeasure & Electromagnetic Attack, BAE Systems. "We take pride in delivering this critical EW capability to keep the U.S. at the vanguard for defense and deterrence."

12:01 EDT Uber announces grocery partnership with The Save Mart Companies - Uber Technologies announced its newest grocery partnership with Modesto, California-based retailer The Save Mart Companies to bring Save Mart, Lucky, and FoodMaxx locations to the Uber Eats app for on-demand and scheduled delivery. Starting today, more than 190 stores in The Save Mart Companies will be available to shop through Uber and Uber Eats, Uber said in a statement. "Save Mart, Lucky, and FoodMaxx stores have been reliably serving residents in California and Nevada for decades, and from one California-based company to another, we're proud to partner with such a beloved regional favorite," said Christian Freese, Uber's Head of Grocery and New Verticals across the US & Canada.

12:00 EDT Oracle falls -11.7% - Oracle is down -11.7%, or -$14.79 to $111.92.

12:00 EDT M3-Brigade Acquisition III Corp. rises 9.5% - M3-Brigade Acquisition III Corp. is up 9.5%, or 96c to $11.12.

12:00 EDT WeWork rises 47.2% - WeWork is up 47.2%, or $1.45 to $4.52.

11:32 EDT Morgan Stanley sees profitability rebounding as Eaton Vance costs phase out

11:22 EDT Morgan Stanley: Credit capital markets performing well

11:12 EDT Health Canada approves updated Moderna COVID-19 vaccineModerna - Health Canada has authorized the use of an updated Moderna vaccine for COVID-19 for all Canadians over the age of six months, according to the information posted on its website. The new vaccine targets the XBB.1.5 variant of the virus that causes COVID-19 and can be given in a single dose to people 5 and older. For children 6 months to 4 years of age, one dose is recommended if previously vaccinated against COVID-19 and two for those who have not been vaccinated. Reference Link

11:03 EDT Fortive subsidiary acquires solar test and measurement products maker Solmetric - Fluke Corp, a wholly owned subsidiary of Fortive, announced that it has acquired California-based Solmetric, which it calls "a market leader in high precision, solar test, and measurement products." Fluke Corporation's President Jason Waxman commented: "Today marks a significant milestone in our journey. Fluke's acquisition of Solmetric reflects our commitment to delivering the best possible products to technicians in the field. Their innovative solar tools and team's deep knowledge in the space, combined with Fluke's passion to advance the electrification of the world more efficiently will enable us to transform this landscape to serve customers better."

10:44 EDT PNC Financial: Expenses also trending better

10:42 EDT PNC Financial expects Q3 NII to be 'a little better than we thought'

10:39 EDT PNC: Current operating model complies with Basel rules - Comments taken from the Barclays Global Financial Services Conference.

10:19 EDT Northern Trust sees Q3 NII 'closer to down 10%' vs. prior guidance of down 5%

10:17 EDT Ford, Honda, BMW to create ChargeScape joint venture - BMW Group (BMWYY), Ford Motor (F) and American Honda Motor (HMC) announced that they have entered into an agreement to create ChargeScape, which they call "a new equally-owned company that will create a single, cost-effective platform connecting electric utilities, automakers and interested electric vehicle customers." "Benefiting both EV customers and the electric utility industry in the U.S. and Canada, ChargeScape will unlock entirely new value that EVs can provide to the electric grid, while enabling EV customers to earn financial benefits through a variety of managed charging and energy-sharing services never before possible with traditional gasoline-powered vehicles. The closing of the transaction and subsequent formation of ChargeScape is pending regulatory approvals, with the company expected to be operational early next year," the companies stated.

10:04 EDT Stratasys ends talks with 3D Systems, reaffirms support of Desktop Metal deal - Stratasys (SSYS) confirmed that the Stratasys board of directors received on September 6 a revised proposal from 3D Systems (DDD) to acquire Stratasys for $7.00 in cash and 1.6387 newly issued shares of 3D Systems common stock per ordinary share of Stratasys, representing a value of $15.26 per share for Stratasys, and a premium of "only" 3% to the unaffected closing stock price of Stratasys ordinary shares as of May 24. "After consultation with its outside financial and legal advisors, and following an extensive due diligence review of 3D Systems, the Stratasys Board unanimously determined that the revised proposal from 3D Systems continues to significantly undervalue Stratasys and does not constitute a 'Superior Proposal' as defined in Stratasys' merger agreement with Desktop Metal (DM). Accordingly, the Stratasys Board has terminated discussions with 3D Systems. The Stratasys Board reaffirms its unanimous support of the pending combination with Desktop Metal," the company announced.

10:02 EDT Stratasys terminates talks with 3D Systems, says revised proposal not 'superior'

10:00 EDT Oracle falls -11.5% - Oracle is down -11.5%, or -$14.55 to $112.16.

10:00 EDT GameStop rises 7.4% - GameStop is up 7.4%, or $1.26 to $18.28.

10:00 EDT WeWork rises 11.9% - WeWork is up 11.9%, or 37c to $3.44.

09:57 EDT Piper Sandler CFO Tim Carter to retire, Kate Clune to succeed - Piper Sandler (PIPR) announced that Tim Carter, CFO at Piper Sandler, will retire in the first quarter of 2024. Kate Clune has been selected to succeed him as chief financial officer. Carter will stay on through April to assist with the transition. As CFO, Clune will be responsible for the financial management of Piper Sandler, including leading investor relations, and will report directly to Abraham. She joins the firm from Evercore (EVR), where she most recently served as treasurer and head of planning and strategy.

09:47 EDT Oracle falls -11.9% - Oracle is down -11.9%, or -$15.08 to $111.63.

09:47 EDT GameStop rises 5.1% - GameStop is up 5.1%, or 86c to $17.88.

09:47 EDT WestRock rises 6.4% - WestRock is up 6.4%, or $2.19 to $36.25.

09:42 EDT Affirm sees higher funding costs in the year, to be a drag on margins - Affirm, at the Barclays Global Financial Services Conference, said it expects funding costs to be driven up this year, which will be a drag from a margin perspective.

09:39 EDT MicroCloud Hologram Inc trading resumes

09:38 EDT Ascent Solar Tech. trading resumes

09:35 EDT Cognyte jumps 20% to $5.54 per share after Q2 results, guidance raise

09:32 EDT Ascent Solar Tech. trading halted, volatility trading pause

09:30 EDT Angion Biomedica Corp trading halted, volatility trading pause

09:19 EDT SciSparc engages bank to identity potential strategic transaction opportunities - SciSparc announced that it has engaged Rosario Capital Ltd., one of Israel' leading investment banks, to identify potential opportunities for a strategic transaction. Rosario Capital will seek and evaluate potential strategic transactions on behalf of the Company, including additional investments in innovative companies, a strategic partnership with one or more parties, or the licensing of one or more of the Company's proprietary technologies or indications. Pending any decision to undertake any such strategic transaction, the Company will continue its development activities in accordance with its existing business strategy.

09:11 EDT Chevron acquires majority stake in Utah clean energy storage hydrogen project - Chevron through its Chevron New Energies division, announced it has closed a transaction with Haddington Ventures to acquire 100% of Magnum Development, and thus a majority interest in ACES Delta which is a joint venture between Mitsubishi Power Americas nd Magnum Development. ACES Delta is developing the Advanced Clean Energy Storage project in Delta, Utah. The Advanced Clean Energy Storage project plans to use electrolysis to convert renewable energy into hydrogen and will utilize solution-mined salt caverns for seasonal, dispatchable storage of the energy. The first project, designed to convert and store up to 100 metric tons per day of hydrogen, is under construction and is expected to enter commercial-scale operations in mid-2025 to support the Intermountain Power Project's "IPP Renewed" initiative. Several other opportunities for the project to produce and supply hydrogen to customers in the utility, transportation and industrial sectors in the western region of the United States are in development..."Reaching this milestone in the development of our hydrogen project will not only have significant benefits to the western U.S. population, but it will also serve as a blueprint for future hydrogen opportunities," said Michael Ducker, senior vice president of Hydrogen Infrastructure for Mitsubishi Power. "With Chevron New Energies' involvement, we expect to expand hydrogen supply more quickly. Together, we are investing in the future of hydrogen, helping to create a viable, cost-competitive market for emerging lower carbon solutions."

09:08 EDT Taboola introduces new AI-powered technology to maximize conversions - Taboola announced significant advancements in its performance advertising-focused bidding technology, called Maximize Conversions. This technology empowers Taboola advertisers to evolve beyond manual and time-consuming cost per click bidding strategies, in favor of simply specifying a budget and having Taboola's algorithm automate the CPC bid to drive as many conversions as possible while staying within budget. "Advertisers deserve technology that drives ROI simply and effectively, and Maximize Conversions delivers exactly that," said Adam Singolda, CEO and founder, Taboola. "We're taking the guesswork out of CPC bidding, making it so that advertisers can simply share their goals, and our AI takes care of the rest. Our AI is trained on first-party contextual signals from more than 9,000 publishers and nearly 600M daily active users, giving advertisers using Maximize Conversions a competitive advantage in reaching customers. We're seeing incredible results from this technology - delivering large amounts of customers, saving costs, time and more. I expect nearly half of our advertisers will adopt this offering in 2024."

09:07 EDT Endeavor Group, WWE close agreement and launch TKO Group - Endeavor Group (EDR) and WWE (WWE) announced the close of their previously announced agreement and the launch of TKO Group (TKO). TKO brings together UFC and WWE to create a new premium sports and entertainment company serving more than one billion young and diverse fans, reaching viewers in 180 countries, and producing more than 350 annual live events.

09:06 EDT Kelso announces patent filed for automated traction optimization method - Kelso Technologies reports that it has filed its first Patent application for the Company's Automated Traction Optimization Method for Vehicle Suspension Systems. The Patent Application forms the Company's initial proprietary claims and intellectual foundation for its automotive wilderness technologies. This patent application filing begins the Company's comprehensive proprietary protection program for its current and future technologies. James Bond CEO of the Company comments: "Kelso is excited to file the first patent application for its automated traction optimization method for vehicle suspension systems. This demonstrates the potential value of Kelso's commitment to initiate evolutionary innovative automotive technologies. Our KXI Wildertec(TM) program is expected to positively impact transportation safety for drivers, workers and the general public operating in the toughest wilderness environments. Our technologies are expected to provide the Company with a multitude of commercial business applications and revenue growth in numerous under serviced wilderness market segments. Management wishes to thank our staff, the engineers, technology experts, wilderness specialists and corporate stakeholders who have made positive contributions to the creation and the ongoing commitment to the potential of our KXI Wildertec(TM) research and development."

09:05 EDT Scilex presented oral, poster presentations on ZTlido at PAINWeek - Scilex Holding, a majority-owned subsidiary of Sorrento Therapeutics, announced that it presented oral and poster presentations at the 2023 Annual PAINWeek Conference on the benefits of ZTlido. The conference was held from September 5-8, 2023 in Las Vegas, NV. Key highlights of the ZTlido1.8% presentation: Review of Multimodal Therapies for the Treatment of Neuropathic Pain: Clinical Implications - In a review of published literature, combinations of systemic agents for the treatment of neuropathic pain were associated with significant adverse events and dropouts while combinations of systemic and topical agents like ZTlido were shown to improve efficacy with minimal additional side effects. Decreased Healthcare Resource Utilization With Lidocaine Topical System 1.8% Compared to Lidocaine 5% Patch: A Retrospective Claims Analysis - Using claims data from OPTUM's de-identified Normative Health Informatics database, the authors showed a decrease in healthcare utilization for outpatient visits, emergency room/urgent care visits and pain procedures in patients who were prescribed ZTlido over patients who were prescribed lidocaine 5% patch. Impact of Adhesion on Patient Satisfaction, Medication Switching and Discontinuation with Lidocaine Topical Patches Based on FDA Adverse Event Reporting and Patient Surveys. - in two on-line patient surveys, poor adhesion from lidocaine 5% patch resulted in poor patient satisfaction leading to product switches and discontinuations, whereas better adhesion associated with ZTlido resulted in an 89% improvement in patient satisfaction, better pain control and improved function.

09:04 EDT Scilex presented oral, poster presentations on Elyxyb - Scilex Holding Company, a majority-owned subsidiary of Sorrento Therapeutics, announced that it presented oral and poster presentations at the 2023 Annual Brain Week Conference on the benefits of Elyxyb. The conference was held from September 6-8, 2023 in Las Vegas, NV. Key highlights of Elyxyb presentation: Pain Freedom with Celecoxib Oral Solution, Ubrogepant, and Rimegepant Through 4 Hours Postdose: Post Hoc Analysis in the Acute Treatment of Migraine: in a post hoc analysis, Elyxyb demonstrated higher pain freedom rates from 60 mins through 3 hours post dose compared to ubrogepant 100 mg and Rimegepant 75 mg. Additionally, Number Needed to Treat was lower while Number Needed to Harm was higher with Elyxyb than ubrogepant and rimegepant. Taken together, these data suggest that to achieve pain freedom with Elyxyb, fewer patients need to be treated and may have less likelihood of being harmed, than with ubrogepant or rimegepant.

09:03 EDT Wix.com announces extended partnership with Stripe - Wix.com announced Tap to Pay on Android to simplify in-person commerce for U.S.-based merchants through an extended partnership with Stripe. Following Wix's recent release of Tap to Pay on iPhone, Wix merchants can now accept secure, contactless payments directly from their Android devices without additional hardware. The Wix Owner App turns any compatible Android device into a Point-of-Sale terminal. By leveraging Wix's advanced and secure POS software, merchants are able to conduct in-person commerce anywhere, anytime, giving their customers a simple, contactless checkout experience. Users can use credit cards, debit cards, Google Pay, and other digital wallets to complete the purchases of their desired products with confidence and ease.

09:02 EDT PayPal, Uber expand relationship - PayPal Holdings (PYPL) and Uber Technologies (UBER) announced an extension of their multi-year relationship, furthering PayPal's role as a key operational partner in Uber's continued growth in both its core and new lines of business in markets all over the world. As part of the agreement, PayPal and Uber will continue to build upon their substantive relationship for global card processing powered by PayPal Braintree. In addition to conventional card processing, Uber will leverage the PayPal Braintree platform to expand its use of domestic debit network routing in several markets, including in the U.S. Uber will also leverage PayPal value-added services including PayPal Payouts and several others that support in creating seamless, high-performance payments experiences for Uber's customers. In addition to the expanded use of payment processing and alternative debit network routing included in the new agreement, Uber will also: Extend its use of payouts with the PayPal Hyperwallet solution, so drivers and couriers will have the option to access their funds instantly through PayPal and Venmo. Launch combined incentives including UberOne in a broad Consumer Rewards program to provide Uber customers with savings when they pay with the PayPal wallet or Venmo at checkout. Leverage the PayPal Chargehound solution to understand how automation can help resolve chargebacks and more quickly produce immediate cost savings. Partner with PayPal on 3DS for advanced customer authentication using Network Tokens, Smart Retries, and Account Updater services for further authorization rate optimization and a more seamless consumer experience.

08:51 EDT Lottery.com regains Nasdaq compliance - Lottery.com announced that on September 8, 2023, it received formal notice from the Listing Qualifications Department of The Nasdaq Stock Market notifying the Company that it has evidenced compliance with the minimum bid price requirement set forth in the Nasdaq Listing Rule 5450(a)(1) and the filing requirement Listing Rule 5250(c).

08:50 EDT NeoVolta partners with Mosaic for solar battery storage financing options - NeoVolta has partnered with sustainable home improvement finance platform Mosaic to offer more homeowners solar energy storage at an affordable rate. "Mosaic's financing options will allow more homeowners to enjoy years of utility savings and long-lasting blackout protection with NeoVolta's energy storage," said CEO Brent Willson, CEO of NeoVolta. "Our solar storage solutions are a smart investment for homeowners, and it's never been easier to get started. With Mosaic financing options, NeoVolta's market is opening up to a much bigger audience. We're thrilled to partner with a world-class fintech platform for sustainable home improvements."

08:47 EDT Vistagen says PH80 showed statistically significant improvement versus placebo - Vistagen announced that PH80, one of the company's five investigational neuroactive nasal sprays, demonstrated statistically significant improvement versus placebo in an exploratory Phase 2A study for acute management of the symptoms of premenstrual dysphoric disorder, or PMDD, including negative mood and physical and behavioral symptoms. The previously unreported randomized, double-blind, placebo-controlled Phase 2A clinical study of PH80 was designed to explore the efficacy, safety, and tolerability of intranasal administration of PH80 for the acute management of PMDD in subjects with a regular menstrual cycle and at least a one-year history of PMDD. The initial study visit occurred after the onset of symptoms. All subjects were administered placebo nasal spray and those who showed no symptom improvement were eligible to return for the second visit, which occurred after the onset of symptoms during the next menstrual cycle. At the second study visit, subjects were randomized to receive a single dose of 0.9 microgram PH80 nasal spray or placebo in the clinic. Subsequent doses of PH80 or placebo were then self-administered at home as-needed, up to four times per day for six consecutive days prior to the estimated day of menses onset. PH80 demonstrated statistically and clinically significant improvement versus placebo in symptoms of PMDD using the subject-rated Penn Daily Symptom Report, or DSR, as early as Day 4 and continuing to Day 6. At Day 6, change from baseline was -12.1 for PH80 versus 7.6 for placebo, showing significant and clinically meaningful improvement. PH80 also demonstrated statistically and clinically significant improvement versus placebo at Day 6 on the clinician-rated Premenstrual Tension Scale, or PMTS, total score where the PH80 change from baseline was 12 versus 7.7 for placebo. PH80 was well-tolerated with no serious adverse events, or AEs. The most common AE was headache, reported by 17% in the placebo group and 7% in the PH80 group. No other treatment-emergent AE occurred more than once per subject. Depression/feeling sad or blue was reported by 0% of PH80 and 68% of placebo-treated subjects; Irritability/persistent anger was reported by less than3% of PH80 and 43% of placebo-treated subjects; Anxiety/tension/on edge was reported by 0% of PH80 and 35% of placebo-treated subjects and difficulty concentrating was reported by 0% of PH80 and 18% of placebo-treated subjects.

08:42 EDT Distribution Solutions launches digital content partnership with Future Today - Distribution Solutions, a division of Alliance Entertainment (NASDAQ: AENT), has announced a new partnership with Future Today, a leading distribution company in the digital space. This partnership will allow Distribution Solutions to expand their reach and offer viewers even more options for its licensed and owned video content. "We are excited to partner with Future Today and offer our film and TV content to even more customers," said Distribution Solutions President, Ben Means. "This partnership allows us to expand our reach on the ad-supported streaming digital platforms."

08:41 EDT Entera Bio announces collaboration with OPKO Biologics - Entera Bio (ENTX) and OPKO Biologics, a subsidiary of OPKO Health (OPK), have entered into a Research Collaboration Agreement. Under the terms of the Agreement, OPKO will supply its proprietary long-acting GLP-2 peptide and certain Oxyntomodulin analogs for the development of oral tablet formulations using Entera's proprietary oral delivery technology. Under the terms of the agreement, Entera and OPKO will each be responsible for specific phases of development of the two oral peptides to the point of demonstrated in vivo feasibility. Further details of the agreement were not made public. "This collaboration with OPKO is important for Entera as it enables us to expand our oral delivery technology across additional high value peptides," said Miranda Toledano, Chief Executive Officer of Entera. "OPKO is a leader in the development and commercialization of highly differentiated, long-acting peptides. Most important, we share a common vision to create first in class peptide treatments to help patients better manage serious, undertreated chronic diseases in a more comfortable way."

08:37 EDT GelStat acquires key intellectual property, assets from Duos Technology - GelStat Corporation (GSAC) announced that its recently formed subsidiary, GSAC Engineering, has concluded the purchase of certain key intellectual property assets from Duos Technologies Group (DUOT). The acquisition included foundational operating environment software, infrastructure, engineering designs, and processes with technology management supporting three medium to high-security facilities being serviced by GSACe. This launch is the first phase in a series of calculated steps being taken by GSACe to establish itself as a competitive alternative in the industrial security market. GSACe plans to combine the acquired assets with certain technological capabilities it has already developed in-house to deploy in an updated solution later this year with a designated customer. "Our acquisition of this technology is a key step in the previously announced transition of the Company," said GelStat CEO Javier Acosta. "We anticipate making further announcements in the near future which will further solidify our entrance into this market and pave the way for revenue growth and profitability in the next few years."

08:36 EDT BTC Digital Ltd. regains compliance with Nasdaq minimum bid price requirement - BTC Digital received a letter from the Listing Qualifications Department of the Nasdaq Stock Market notifying the company that it has regained compliance with the Nasdaq's minimum bid price requirement and the matter is closed.

08:34 EDT Color Star Technology signs non-binding LOI to acquire JingXiang Australia - Color Star Technology has entered into a non-binding letter of intent for the planned acquisition of over 60% of shares of JingXiang Australia. JingXiang Group provides multiple new digital services that brings electronic sports to hotels. JingXiang's three main services include providing a fully-loaded supercomputing platform, an esports software as a service for hotels, as well as a central reservation system for these hotels. In the future, these three services will be consolidated and become provided solely by JingXiang Australia. In response to the growing market of esports hotels, JingXiang launched a CRS catering specifically to this emerging business. Completion of the transaction is subject to due diligence investigations by the relevant parties, the negotiation and execution of a definitive agreement, satisfaction of the conditions negotiated therein including approval of the Board of Directors and other customary closing conditions. There can be no assurance that a definitive agreement will be entered into or that the proposed transaction will be consummated.

08:34 EDT DiaMedica appoints Ambarish Shah, Ph.D. as Chief Technology Officer - DiaMedica Therapeutics (DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and cardio-renal disease, announced the appointment of Ambarish Shah, Ph.D. as Chief Technology Officer. Dr. Shah will lead the development of DiaMedica's manufacturing operations for the late-stage drug candidate DM199. Since May 2023, Dr. Shah has been advising DiaMedica as it worked through the final resolution of the clinical hold on the investigational new drug application for its ReMEDy2 clinical trial of DM199 in acute ischemic stroke patients. Shah has over 25 years of experience in advancing biopharmaceuticals from early stage to commercialization. He was previously the Vice President and Head of Global Vaccines Development at CSL Seqirus where he was accountable for end-to-end chemistry, manufacturing and control in the development of vaccines. Prior to that position, he was Executive Director, Head of Drug Product Development at Bristol-Myers Squib (BMY). His prior experience comprised increasingly impactful roles at AstraZeneca (AZN), GlaxoSmithKline (GSK) and Pfizer (PFE).

08:32 EDT Intel to sell 10% stake in IMS Nanofabrication business to TSMC - Intel (INTC) announced that it has agreed to sell an approximately 10% stake in the IMS Nanofabrication business, or IMS, to TSMC (TSM). TSMC's investment values IMS at approximately $4.3B, consistent with the valuation of the recent stake sale to Bain Capital Special Situations. Intel will retain majority ownership of IMS, which will continue to operate as a standalone subsidiary under the leadership of CEO Elmar Platzgummer. The transaction is expected to close in the fourth quarter of 2023. In June, Intel announced an agreement to sell an approximately 20% stake in IMS to Bain Capital.

08:26 EDT WestRock enters merger agreement with Smurfit Kappa - In a regulatory filing, WestRock entered into a transaction agreement with Smurfit Kappa Group, a public limited company incorporated in Ireland, Cepheidway, a private limited company incorporated in Ireland and Sun Merger Sub, a Delaware limited liability company and a wholly owned subsidiary of ListCo. The agreement provides, among other things, and subject to the satisfaction or waiver of the conditions set forth therein, that pursuant to a scheme of arrangement each issued ordinary share of Smurfit Kappa will be exchanged for one ordinary share of ListCo, as a result of which Smurfit Kappa will become a wholly owned subsidiary of ListCo, and following the implementation of the scheme, Merger Sub will merge with and into the company, with the company surviving the merger as a wholly owned subsidiary of ListCo. As a result of the merger, each share of common stock, par value $0.01 per share, of the company, other than shares of company common stock issued and outstanding immediately prior to the merger effective time and held by a holder of record who does not vote in favor of the approval and adoption of the Agreement and properly demands appraisal of such shares, will be converted into the right to receive one ListCo Share and $5.00 in cash and all shares of company common stock owned by the company, any subsidiary of the company, Smurfit Kappa, Merger Sub or any of their respective Subsidiaries will be cancelled and will cease to exist, and no consideration will be delivered in exchange therefor. Following the completion of the transaction, former Smurfit Kappa shareholders are expected to hold approximately 50.4% of ListCo and former stockholders of the company are expected to hold approximately 49.6% of ListCo. Following completion of the transaction, it is expected that the ListCo Shares would be registered under the Exchange Act and listed on the New York Stock Exchange and listed on the Standard Listing segment of the Official List of the Financial Conduct Authority, or FCA, and admitted to trading on the main market for listed securities of the London Stock Exchange, or LSE.

08:18 EDT Bolt Biotherapeutics announces issuance of U.S. patent covering BDC-3042 - Bolt Biotherapeutics announced the issuance of the first and foundational patent covering BDC-3042. The U.S. Patent and Trademark Office, USPTO, issued U.S. Patent 11,753,474 titled "Anti-Dectin-2 Antibodies," on September 12, 2023. "The issuance of this patent is an important milestone in protecting the composition of matter and methods of treatment for our BDC-3042 clinical candidate," explained Justin A. Kenkel, Ph.D., BDC-3042 co-inventor and Principal Scientist at Bolt Biotherapeutics. "This patent covers antibodies with a novel mechanism of action that leverages Dectin-2 agonism to repolarize tumor-associated macrophages into immunostimulatory, anti-tumor macrophages. We are on track to enter the clinic with BDC-3042 this year and are excited by the potential for this new approach to treat many different types of cancer."

08:16 EDT Exelixis in $80M deal with Insilico for global rights to develop ISM3091 - Exelixis (EXEL) and Insilico Medicine announced that the companies have entered into an exclusive license agreement granting Exelixis global rights to develop and commercialize ISM3091, a potentially best-in-class small molecule inhibitor of USP1, which has emerged as a synthetic lethal target in the context of BRCA-mutated tumors. Under the terms of the agreement, Insilico granted Exelixis an exclusive, worldwide license to develop and commercialize ISM3091, and other USP1-targeting compounds, in exchange for an upfront payment to Insilico of $80M anticipated in the third quarter 2023. Insilico is also eligible to receive future development, commercial, and sales-based milestone payments, as well as tiered royalties on net sales. "ISM3091 represents a potentially best-in-class approach to inhibiting USP1, an important oncology target with broad applicability in BRCA-mutant tumors," said Dana Aftab, Ph.D., Executive Vice President, Discovery and Translational Research and Chief Scientific Officer, Exelixis. "We believe preclinical data on ISM3091's potent anti-tumor activity, tolerability, and pharmacokinetics set the compound apart from competing USP1 inhibitors and make it an important addition to Exelixis' growing clinical-stage pipeline. Following the FDA's clearance of Insilico's IND earlier this spring, we're looking forward to accelerating phase 1 trial enrollment." "ISM3091 is the third clinical-stage program made possible by Chemistry42, Insilico Medicine's generative AI platform for small molecule drug discovery," said Alex Zhavoronkov, Ph.D., founder and CEO of Insilico Medicine. "The compound's novel structure, anti-tumor activity, and excellent drug-like properties give it significant potential as a differentiated program directed at BRCA-mutant tumors, which include forms of ovarian, prostate, and breast cancer. This program attracted significant interest from multiple potential partners in the pharmaceutical industry, but we were most impressed by the level of technical expertise and development and commercial capabilities of Exelixis. With a track record of commercial and clinical development success in oncology, Exelixis is the best partner to take ISM3091 forward, and we're excited to see the program take flight as a component of the company's pipeline behind cabozantinib, its global oncology franchise." USP1 facilitates DNA damage repair by removing ubiquitin from multiple substrates including proteins that stabilize the replication fork. A small molecule discovered using Insilico Medicine's generative AI platform with extensive multiparameter optimization capabilities, ISM3091 was designed to inhibit the activity of USP1. In preclinical experiments, ISM3091 was found to be potently efficacious against multiple tumor cell lines and in vivo models with BRCA mutations, as well as in homologous recombination DNA repair proficient models, both as a single agent and in combination with PARP inhibitors. It is also well tolerated in different species with a high margin of safety. Insilico disclosed select data in a poster presentation at the American Association for Cancer Research Annual Meeting in April 2023. On April 17 the FDA cleared the initial IND for ISM3091 for the treatment of patients with solid tumors.

08:13 EDT e.l.f. Beauty exec sells $1.71M in common stock - In a regulatory filing yesterday, e.l.f. Beauty disclosed that its SVP of Operations Joshua Franks sold 12.7K shares of common stock on September 7th in a total transaction size of $1.71M. The company's director Maureen Watson also sold $1.08M in stock on September 8th as part of option expiry. Shares of e.l.f. Beauty are down 1.1% in pre-market trading at $134.00.

08:10 EDT Salesforce, Google team for productivity, 'powered by Generative AI' - Salesforce (NYSE: CRM) and Google (GOOG) announced an expansion of their strategic partnership to bring together Salesforce, and Google Workspace, to drive productivity with AI. "This partnership will deliver new bidirectional integrations that allow customers to bring together context from Salesforce and Google Workspace, including Google Calendar, Docs, Meet, Gmail, and more, to power generative AI experiences across platforms With these integrations, users will be able to seamlessly work across platforms through Salesforce and Google Workspace's generative AI assistants, Salesforce's Einstein Copilot, and Duet AI in Google Workspace. Customers can use their own account, contact, and opportunity data from Salesforce to generate customized G This expanded partnership will help drive increased productivity by providing the right data and context at the right time, and unlocking generative AI benefits in the flow of work. With this integration, users will be able to: -- Generate personalized content across Google Workspace and Salesforce: Users will be able to generate personalized and contextual Workspace content, including emails in Gmail, content in Google Docs, and more, from Workspace or Salesforce, by seamlessly accessing relevant Salesforce information on prior meetings, customer interactions, and sales outcomes: Keep Salesforce records up-to-date with context from Google Workspace Users will be able to leverage Google Workspace data to automatically..Drive automation at scale: Users will be able to automate processes and...," said the release in part.

08:09 EDT EuroDry announces agreement to acquire three eco ultramax bulkers - EuroDry announced that it has agreed to acquire three Ultramax bulkers, M/V Giants Causeway, a 63,197 dwt drybulk vessel built in 2015, M/V Sadlers Wells, a 63,153 dwt drybulk vessel built in 2015 and M/V Gallileo, a 63,177 dwt drybulk vessel built in 2014, for a total price of about $65 million. The vessels are expected to be delivered to the Company during October and November 2023. The acquisitions will be financed by the Company's own funds and bank debt. Aristides Pittas, Chairman and CEO of EuroDry, commented: "We are pleased to announce the acquisition of three Eco Ultramax drybulk vessels, all built during 2014 and 2015. The vessels are sisterships of our own M/V Alexandros P which was built at the same shipyard in 2017. This acquisition further expands our modern fleet cluster at a time when we believe that the market fundamentals, especially the low orderbook, are very supportive of a healthy market over the next two to three years. While demand side -geopolitical and economic- uncertainties remain, we believe that the risks are tilted to the upside and the present level of the market presents a great opportunity to expand our fleet with high quality units of known design. We expect these vessels to make significant contributions to our EBITDA."

08:08 EDT Nuvectis Pharma announces initiation of NXP9000 Phase 1a trial - Nuvectis Pharma announced the initiation of a Phase 1a dose escalation clinical trial of NXP900, its novel inhibitor of the SRC/YES1 kinase family. The study is designed to evaluate the safety, tolerability and pharmacokinetic properties of NXP900 in patients with advanced solid tumors. "Advancing NXP900 into its first in human clinical trial is an important milestone for Nuvectis," said Ron Bentsur, Co-Founder, Chairman and Chief Executive Officer of Nuvectis, who added, "We believe that NXP900's unique mechanism of action, which completely shuts down signaling via SFK, in conjunction with its high target specificity, differentiates it from other multi-kinase inhibitors that also inhibit SFK and provide it with the potential to become the first SFK inhibitor for the treatment of solid tumors."

08:07 EDT Ascent Solar achieves new benchmark in cell production efficiency - Ascent Solar Technologies announced that it has achieved a cell production efficiency increase, with a new benchmark of 15.5% in its CIGS solar technology, a significant increase from the 10.8% standard efficiency measured for production material in 2012. This increase is the result of focused innovation and a giant step toward the improved efficiencies that ASTI intends to deliver through continued process optimization and development of alternate chemistries. "We are thrilled with the rapid progress optimization for our CIGS technology that has taken place over just a few short weeks," said Paul Warley, ASTI's Chief Executive Officer. "As we continue to optimize our technology and processes, we expect to move even closer to reaching our efficiency goal of 18% in the near future, furthering our long-term mission of increasing the rate of global thin-film PV adoption."

08:06 EDT Ceridian announces furthering ints sustainability commitment - Ceridian announced it is furthering its sustainability commitment with two new actions that demonstrate its ambition to reduce its annual greenhouse gas emissions in line with the goals of the Paris Agreement and the best available climate science. The first is a new target to reduce Scope 3 emissions intensity per revenue by more than 50% before 2030 from a 2019 baseline. The second is a commitment to work with the Science Based Targets initiative to validate this new Scope 3 target, its existing Scope 1 and 2 emissions reduction target, and its ongoing pledge to source 100% renewable electricity across its global facilities.

08:06 EDT Lisata Therapeutics announces first patient treated in BOLSTER trial - Lisata Therapeutics announced treatment of the first patient in the head and neck squamous cell carcinoma cohort of the BOLSTER trial, by Dr. Alexander N. Starodub, a principal investigator of the study, at The Christ Hospital in Cincinnati, Ohio. "We are excited to announce treatment of the first patient in the second-line head and neck squamous cell carcinoma cohort of the BOLSTER trial. Head and neck squamous cell carcinoma, which usually begins in the mucosal surfaces of the mouth, throat or voice box, is a rare and aggressive form of solid tumor cancer that is diagnosed in roughly 67,000 patients a year in the U.S. Most head and neck cancers eventually spread to the lymph nodes nearest to the affected area and can become incurable or uncontrollable resulting in advanced or terminal stage disease. The BOLSTER trial gives us the opportunity to evaluate the potential of LSTA1 in a variety of solid tumor settings in combination with corresponding standards-of-care and will provide direction on potential next steps in development," stated Kristen K. Buck, M.D., Executive Vice President of R&D and Chief Medical Officer of Lisata. "Now that the first patient in BOLSTER has been treated, we expect an uptake in enrollment in the coming quarters. We remain committed to developing groundbreaking therapies that can transform the outcomes of individuals facing these life-threatening conditions."

08:05 EDT Comscore renews expanded partnership with Green Bay Packers - Comscore announced the continuation of its media measurement collaboration with the Green Bay Packers. The two-year agreement includes the continued use of Comscore's local television and digital measurement solutions as well as an extension of Comscore's social measurement platform.

08:03 EDT Infinera announces suite of ICE-X coherent pluggables - Infinera announced its plan to make available to its customers ICE-X intelligent coherent pluggables and compound semiconductor components that will be manufactured in the U.S. and compliant with the Build America, Buy America requirements recently released by the Commerce Department for the Broadband Equity, Access, and Diversity program. Leveraging its domestic optical compound semiconductor fabrication facility in California and advanced testing and packaging facility in Pennsylvania, Infinera's coherent optical solutions enable network operators to efficiently scale their networks, driving down cost per bit and power per bit while helping them meet Build America, Buy America requirements. Infinera's U.S.-based semiconductor production also provides improved supply chain security and resiliency.

08:02 EDT Constellium received ASI certificate for facilities in Muscle Shoals, Alabama - Constellium announced that it has received the Aluminium Stewardship Initiative, ASI, performance Standard certificate for its facilities in Muscle Shoals, Alabama, and Bowling Green, Kentucky. This certification, verified by an independent third-party audit, means that the plants operate according to a strict set of governance, environmental, and social standards, including greenhouse gas emissions, biodiversity and labor rights. "Receiving the ASI certification is an extraordinary achievement for our Muscle Shoals and Bowling Green facilities, and demonstrates our commitment to manufacture our products in a responsible and sustainable way," said Fred Pearson, Director of Environment and Sustainability at Constellium Muscle Shoals. "Our recycling capacity, coupled with this certification, is a step further to respond to the demands of our customers and society."

08:00 EDT Draganfly awarded state corrections contract - Draganfly announces that it has been awarded a contract to provide its Vital Intelligence technology to a state corrections agency to its facilities enhance security and efficiency for the benefit of the community, the staff, and the inmates. "The corrections market represents an important and significant market for Draganfly's Drone, AI and Counter Drone solutions and we are honored to have been awarded a state-wide contract for this Tier One Government Customer, said Cameron Chell, President and CEO of Draganfly.

07:40 EDT PyroGenesis signs $2.25M plasma torch contract for PFAS removal - PyroGenesis Canada announces the signing of a contract valued at US $1.65 million from a U.S. corporation geared to destroy Perfluoroalkyl and Polyfluoroalkyl Substances on behalf of a large operator of public water systems. The name of the Client will remain anonymous for confidentiality reasons. This Contract includes a 20% upfront payment totaling approximately US $380,000 which has been received. "As disappointing as it was to suspend our participation in the previous iteration of this project, we are happy that discussions have since developed that enable us to showcase PyroGenesis' plasma torch capabilities when it comes to addressing the critical problems posed by PFAS. Of note, this is the second contract in recent weeks, that will demonstrate the capabilities of PyroGenesis' ultra-high temperature plasma torch," said P. Peter Pascali, CEO of PyroGenesis. "Slowly but surely, PyroGenesis' long-term approach to its various business segment is starting to bear fruit."

07:40 EDT Wells Fargo 'very comfortable' with FY23 NII guidance, says CFO - Wells Fargo previously said 2023 net interest income is expected to be ~14% higher than the full year 2022 level of $45B.

07:39 EDT Denbury announces expiration of HSR Act waiting period for Exxon Mobil deal - Denbury (DEN) announced the expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended, with respect to the previously-announced agreement for ExxonMobil (XOM) to acquire all outstanding shares of Denbury at an exchange ratio of 0.84 shares of ExxonMobil for each Denbury share. The expiration of the HSR Act waiting period was a condition to the closing of the pending transaction. Completion of the transaction is subject to the satisfaction of the remaining customary closing conditions, including approval by Denbury stockholders. The transaction is expected to close in the fourth quarter.

07:38 EDT Wells Fargo seeing 'more of the same' on deposit side, says CFO

07:37 EDT Mind Medicine completes enrollment in study of lysergide D-tartrate for GAD - Mind Medicine announced that it has completed enrollment and dosing in Study MMED008, the Company's Phase 2b study evaluating MM-120,lysergide D-tartrate, for the treatment of GAD. "Completion of enrollment of this study is a significant milestone for MindMed and moves us one step closer to our goal of transforming the treatment of GAD for the millions suffering from the disorder," said Robert Barrow, Chief Executive Officer and Director of MindMed. "Thanks in large part to the enthusiasm we have seen regarding MM-120 among investigators and patients, as well as the strong execution of our team, we were able to enroll almost 200 participants in this trial in just over a year. We anticipate sharing topline results during the fourth quarter of this year."

07:37 EDT Abeona Therapeutics appoints Vasanthavada as CCO, Head of BD - Abeona Therapeutics announced the appointment of Madhav Vasanthavada, Ph.D., M.B.A. to the role of Chief Commercial Officer, CCO, and Head of Business Development, BD, effective immediately. In this capacity, in addition to his current BD responsibilities, Dr. Vasanthavada will oversee all aspects of commercial strategy, planning and operations as Abeona prepares for a potential launch of EB-101, its investigational, genetically engineered autologous cell therapy for recessive dystrophic epidermolysis bullosa. Over the past year, as Abeona's Head of BD, Dr. Vasanthavada's efforts to assess EB-101's commercial opportunity informed the Company's strategy to prepare for a U.S. commercial launch without depending on a partner.

07:34 EDT Altimmune announces completion of dosing in Phase 2 MOMENTUM trial - Altimmune announced the completion of dosing in its 48-week Phase 2 MOMENTUM trial evaluating the efficacy and safety of pemvidutide in subjects with obesity or overweight. Pemvidutide is a novel, investigational GLP-1/glucagon dual receptor agonist under development for the treatment of obesity and non-alcoholic steatohepatitis. "We remain on target to announce topline 48-week results from our Phase 2 MOMENTUM trial in the fourth quarter of this year," said Vipin Garg, Ph.D., President and CEO of Altimmune. "We believe pemvidutide offers a highly differentiated product profile that includes significant reductions in body weight, serum lipids and liver fat, without increases in heart rate or other cardiovascular safety signals. We also believe this combination of attributes has the potential to demonstrate best in class benefits in future cardiovascular outcome trials."

07:33 EDT Syneos Health, Oracle expand relationship to accelerate patient recruitment - Syneos Health (SYNH) announced a strategic collaboration that will expand its relationship with Oracle (ORCL). Using the Oracle Cerner Learning Health Network and elements of Oracle's suite of study startup solutions, the companies seek to help reduce the time it takes to recruit patients for clinical studies and increase the diversity of patient populations participating in medical research. "At Syneos Health, we are committed to closing the gaps that exist in clinical trial recruitment - from helping identify the right patients for a study to ensuring a diverse patient population," said Baba Shetty, President, Technology & Data Solutions, Syneos Health. "Collaborating with Oracle will demonstrate our goal of continued investment in technology and data solutions that accelerate clinical development and optimize performance for our customers."

07:32 EDT Neurocrine announces 'positive' data from Phase 3 study of crinecerfont - Neurocrine Biosciences announced positive top-line data from the Phase 3 CAHtalyst Adult Study evaluating the efficacy, safety, and tolerability of crinecerfont in adults with classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency. The Phase 3 study met its primary endpoint at Week 24, demonstrating that treatment with crinecerfont resulted in a statistically significant percent reduction in daily glucocorticoid dose versus placebo while maintaining androgen control. The study also met important key secondary endpoints, with a statistically significant decrease in androstenedione at Week 4 versus placebo. At Week 24, approximately 63% of patients on crinecerfont achieved a reduction to a physiologic GC dose versus approximately 18% on placebo. Crinecerfont was generally well tolerated. The most common adverse events during the double-blind, placebo-controlled period of the trial were fatigue, headache, and coronavirus infection. There were few serious adverse events, with none assessed as related to crinecerfont.

07:30 EDT CorVel announces first Generative AI module - CorVel announced the release of its initial Generative AI module. A new addition to CorVel's CogencyIQ service offerings, the module will leverage machine learning to interpret medical records for adjusters and prompt immediate actions. "Our approach to Generative AI is marked by intentionality, fostering collaborative efforts with our team and partners. Our unwavering commitment lies in leveraging technology to elevate the efforts of our professional staff and improve the outcomes delivered. We also see generative AI as an efficient approach to mitigate labor-related challenges by offering guidance to upcoming generations of professionals," said Michael Combs, President and CEO, of CorVel.

07:17 EDT Macy's names Olivier Bron as CEO of Bloomingdale's - Macy's announced that it has named Olivier Bron CEO of Bloomingdale's, with an anticipated start date in early November. Bron will report directly to Tony Spring, who was appointed President and CEO-Elect of Macy's, Inc. in March following a 36-year career at Bloomingdale's. As CEO of Bloomingdale's, Bron will lead overall strategy across all facets of the business. He will also be responsible for building upon Bloomingdale's curated offering of designers, advanced contemporary, and exclusive private brands. Bron was most recently CEO of Central Group's Central and Robinson Department Stores in Thailand.

07:16 EDT 2seventy Bio CEO Leschly to step down after identification of successor - Nick Leschly has informed the Company's Board of Directors that he intends to step down as CEO upon the Board's identification of his successor. The Company expects that Mr. Leschly will be appointed Chairman of the Board upon this transition. The Board has retained an executive recruitment firm to assist with the search for Mr. Leschly's successor as CEO. "After nearly 14 years as CEO of bluebird and 2seventy I feel beyond grateful and humbled to have had the opportunity to help bring four cell therapies to patients and do our part to advance the field," said Nick Leschly, chief kairos officer. "I very much look forward to continuing to work closely with the board and leadership team to advance 2seventy's mission for patients." Additionally, Chip Baird, formerly Chief Financial Officer, is now Chief Operating Officer expanding his responsibilities to include finance, corporate development, investor relations and corporate communications as well as portfolio and program/alliance management.

07:14 EDT Humacyte announces results from Phase 2/3 trial of HAV - Humacyte announced positive top line results from its V005 Phase 2/3 trial of the Human Acellular Vessel, HAV, in vascular trauma repair. The single-arm clinical trial was a success and showed that the HAV in this study had higher rates of patency, and lower rates of amputation and infection, compared to historic synthetic graft benchmarks. Humacyte plans to file a Biologics License Application, BLA, for the treatment of vascular trauma with the Food and Drug Administration, FDA, during the 4th quarter of 2023. The V005 trial was a single-arm study conducted in the United States and Israel in patients with arterial injuries resulting from gun shots, workplace injuries, car accidents, or other traumatic events. A total of 69 patients were enrolled in the V005 trial, of which 51 had vascular injury of the extremities and comprised the primary evaluation group for the study. The V005 trial was a success, and the principal comparison of 30-day secondary patency for the HAV in the clinical trial was 90.2% for the extremity patients compared to 81.1% historically reported for synthetic grafts. Primary patency for total HAV patients and for extremity patients was 81.2% and 84.3%, respectively, although no comparison to synthetic graft primary patency was possible since this measure was not reported in the benchmark publications. For the secondary comparison of amputation rates, the HAV demonstrated an improvement with a rate of 9.8% for extremity patients compared to 20.6% historically reported for synthetic grafts. For the secondary comparison of infection rate, the HAV demonstrated an improvement, with a rate of 2.0% for the extremity patients compared to 8.9% historically reported for synthetic grafts. There were no unexpected safety signals for the HAV in this study. An expanded presentation of the results of the V005 trial is expected to be made at the Veith Symposium, a major vascular surgery meeting, in New York City on November 16, 2023. Humacyte is currently preparing a BLA for use of the HAV in urgent arterial repair following extremity vascular trauma when synthetic graft is not indicated, and saphenous vein is not feasible to the FDA before the end of the year.

07:11 EDT 22nd Century adds 1,200 drug store locations selling VLN in five states - 22nd Century Group announced its FDA authorized VLN reduced nicotine content cigarettes designed specifically to promote tobacco harm reduction are now available at more than 1,200 drug store locations across Texas, Florida, Illinois, North Carolina and Georgia beginning in September. With this most recent addition, VLN is available in more than 4,000 stores across 16 states, compared with approximately 1,100 stores at July 1. "We are excited to launch the first drug store chain selling our FDA authorized VLN tobacco harm reduction products, adding 1,200 stores across five key state markets to our growing roster of convenience store points of sale," stated John Miller, interim Chief Executive Officer of 22nd Century Group. "VLN) offers a new, clinically researched solution helping adult smokers reduce their smoking rate and the associated harms of smoking over time."

07:11 EDT Guardforce AI secures two-year contract for end-to-end cash management solution - Guardforce AI announced that its subsidiary, Guardforce Cash Solutions Security Company Limited, has secured a two-year contract with a pre-existing client for its end-to-end cash management solutions, further strengthening the Company's leading position in Thailand. The end-to-end cash management solution in this contract renewal includes Guardforce Digital Machine, Cash-in-Transit, Cash Processing Centre, and Change Fund services across four locations in Bangkok, Thailand. Kee Yun Kwan, Chief Operating Officer of Guardforce AI, stated, "We're grateful to our client for this contract award. We have been working with them for many years and are excited to expand the scope of our services. We're the only company in Thailand that provides complete end-to-end cash management solutions. Besides strengthening our position in the market, the relationships we maintain with our clients provide us a solid foundation to expand into other business sectors such as robotics."

07:10 EDT 2seventy Bio to reduce workforce by 40% for $130M + in savings in FY24-FY25 - "The difficult but necessary changes we are making to our workforce, our programs and our cost structure reflect our commitment to advancing our pipeline and achieving value creating milestones with existing cash," said Chip Baird, chief operating officer. "Our U.S. Abecma collaboration provides a source of revenue to offset investment in our pipeline programs, and while we continue to be optimistic about Abecma's future, particularly given the potential third-line label expansion at the end of the year, we are planning conservatively. We expect today's changes will preserve runway into at least 2026, and we will continue to focus on careful expense management and thoughtful capital allocation while staying true to our mission of driving programs forward for patients in need. I echo Nick's gratitude to the members of our team who will be departing 2seventy and look forward to continuing to uphold 2seventy's unwavering focus on patients as we move into a new chapter." Elimination of 176 roles, representing approximately 40% of our workforce Expected annualized cost savings of at least $65 million, or approximately $130 million in the 2024-2025 period; additional savings possible as we continue rigorous efforts to right-size facilities and related external spend by 2025 to better reflect our current needs. One-time restructuring costs of approximately $9 M, primarily incurred in the third quarter of 2023. Implemented a capital-efficient translational development paradigm blending internal manufacturing (270-MPH), our expanded JW Therapeutics collaboration as well as select academic centers to efficiently explore our innovative cell therapies in the clinic Current balance of cash, cash equivalents, and marketable securities expected to support operations into 2026.

07:08 EDT Emerita Resources files exploitation license application for IBW Project - Emerita Resources announces that through its wholly-owned Spanish subsidiary, Emerita Resources Espana S.L.U., it has submitted an application to the "Delegacion Territorial de Energia y Minas in Huelva province, Junta de Andalucia" for an exploitation licence for Emerita's wholly-owned Iberian Belt West project. The Exploitation Licence in Spain, when granted, has a 30-year term and can be extended for two subsequent 30-year periods. Under Spanish regulations, in support of its Exploitation License application, Emerita has 3 months to submit certain additional documentation to supplement the application for the Exploitation Licence including an environmental impact study and mining plan. All documentation required to support the Exploitation Licence is currently being prepared by Emerita in a form designed to meet the criteria required to complete the Exploitation Licence application.

07:07 EDT Lucy Scientific acquires BlueSky Wellness in all-stock transaction - Lucy Scientific Discovery announces an agreement to acquire BlueSky Wellness and its portfolio of brands. This transaction expands Lucy's footprint into the growing global wellness category by adding psychotropic products to its capabilities. Upon finalization of this acquisition, the BlueSky team will market Lucy's MINDFUL brand, as well as a diverse range of psychotropic products for all 3 companies' brands utilizing its e-commerce platform. Under the terms of the agreement, BlueSky's shareholders will receive 3.5 million shares of Lucy Scientific's stock, as well as annual earn out payments based on a multiple of annual EBITDA in each of the next five years. Upon closing of the High Times and Blue Sky Wellness transactions, Lucy Scientific expects to have approximately 25 million shares issued and outstanding; and projects the two transactions on a consolidated basis to add a minimum of $30 million of revenue and $10 million of EBITDA for the first twelve month period after closing. Lucy expects to complete the acquisition within 90 days, and will work closely with the BlueSky team during the transition.

07:06 EDT 2seventy Bio announces strategic restructuring of business operations - 2seventy bio announced a restructuring of its business operations and research and development model to significantly reduce costs while supporting the execution of a prioritized plan for the long-term growth of the company. "2seventy's mission remains the same: to unleash the power of the T-cell and develop un-incremental treatments for people living with cancer," said Nick Leschly, chief kairos officer. "However, the macro environment for oncology cell therapy companies and the near-term headwinds we have seen in our own business have led us to examine how we pursue our mission. Today we are taking hard but necessary steps to streamline our team and optimize our R&D approach and cost structure. In this process, we have focused on how to move efficiently and more cost effectively to develop innovative therapies for patients and create value for shareholders. Unfortunately, we will be saying goodbye to many highly talented and committed members of our team. I want to thank each of them for their amazing dedication to 2seventy and our mission to help those in need, doing everything we can to deliver more TIME." "The difficult but necessary changes we are making to our workforce, our programs and our cost structure reflect our commitment to advancing our pipeline and achieving value creating milestones with existing cash," said Chip Baird, chief operating officer. "Our U.S. Abecma collaboration provides a source of revenue to offset investment in our pipeline programs, and while we continue to be optimistic about Abecma's future, particularly given the potential third-line label expansion at the end of the year, we are planning conservatively. We expect today's changes will preserve runway into at least 2026, and we will continue to focus on careful expense management and thoughtful capital allocation while staying true to our mission of driving programs forward for patients in need. I echo Nick's gratitude to the members of our team who will be departing 2seventy and look forward to continuing to uphold 2seventy's unwavering focus on patients as we move into a new chapter."

07:05 EDT Avalo Therapeutics enters into agreement to divest AVTX-800 series - Avalo Therapeutics announced it entered into a purchase agreement with AUG Therapeutics to sell its rights, title and interest in, assets relating to AVTX-801, AVTX-802 and AVTX-803. AUG will pay an upfront payment of $150,000, as well as, for each compound, make a contingent milestone payment of $15,000,000 if the first Food and Drug Administration approval is for an indication other than a Rare Pediatric Disease, or up to 20% of certain payments, if any, granted to AUG upon any sale of any priority review voucher granted to AUG by the FDA, net of any selling costs. Additionally, AUG will assume up to $150,000 of certain liabilities incurred prior to the date of the Purchase Agreement and assume all costs relating to the 800 Series from the date of the Purchase Agreement. The transaction is expected to close in the fourth quarter of 2023, subject to customary closing conditions, including obtaining certain third-party consents. "We are excited to announce the transfer of our 800 series programs for the treatment of congenital disorders of glycosylation to AUG. In AUG's hands, these programs could advance to provide reliable treatments for patients in need. This divestiture also reaffirms Avalo's unwavering commitment to executing our strategic focus on our immunology assets, which we believe hold the greatest value and potential for our shareholders," stated Dr. Garry Neil, MD, Chief Executive Officer, and Chairman of the Board at Avalo Therapeutics. "This transaction will have an immediate positive impact on our cash flow and reduce the utilization of our internal resources for non-core assets, while also maintaining substantial upside potential for Avalo upon program success."

07:04 EDT European Wax Center publishes 2022 ESG Report - European Wax Center announced the release of its 2022 Environmental, Social and Governance, ESG, Report, highlighting the Company's efforts to build a more confident, inclusive and sustainable community. David Berg, Chief Executive Officer of European Wax Center, Inc. stated: "I am thrilled to announce the release of our inaugural ESG Report, outlining our efforts to build a better, more sustainable and inclusive future. Through our relentless focus on our core values, we've been doing much of this work long before our IPO in 2021. This report reinforces our commitment to sustainable business practices that deliver value for all stakeholders and marks a significant milestone in our ESG journey."

07:03 EDT Lyra Therapeutics announces results from BEACON Phase 2 study of LYR-220 - Lyra Therapeutics announced positive topline results from the BEACON Phase 2 clinical study of LYR-220 in adult patients with CRS, with and without polyps, who have had prior ethmoid sinus surgery. The study met its primary safety endpoint, with no serious adverse events observed. Most commonly reported adverse events included sinusitis, nasopharyngitis, bronchitis, and COVID-19. LYR-220 significantly improved important patient reported outcome measures compared to sham control: Statistically significant improvement in a composite of the 3 cardinal symptoms of CRS at week 24; Statistically significant improvements in Sino-Nasal Outcome Test score compared to sham control at week 24; Statistically significant improvement in a composite of the 3 cardinal symptoms of CRS as early as week 4; Statistically significant improvements in SNOT-22 were observed as early as week 2; Improvements in SNOT-22 were sustained throughout the study and clinically meaningful with almost twice the minimal clinically important difference observed at week 24 compared to sham. LYR-220 is a bioresorbable nasal matrix designed to deliver six months of continuous anti-inflammatory medication to the sinonasal passages for the treatment of CRS. Topline results from the BEACON study of LYR-220 will be presented at the American Rhinologic Society 69th Annual Meeting on September 30, 2023, in Nashville, TN. Full results will be submitted for future publication.

07:01 EDT Hamilton Lane announces CEO succession plan - Hamilton Lane announced that long-time executives Erik Hirsch and Juan Delgado-Moreira have been appointed Co-CEOs, effective January 1, 2024. They succeed Mario Giannini, who, after 22 years as Hamilton Lane's CEO, will join Hartley Rogers as Executive Co-Chairman. Rogers has served as Chairman of the Board since 2005.

06:58 EDT 2seventy Bio and JW Therapeutics to expand therapy R&D partnership - 2seventy Bio and JW Therapeutics announced their intention to expand their strategic alliance. The expansion, based on the partnership that was established last year, builds upon the companies' translational and clinical cell therapy development platform originally designed to more rapidly explore T cell-based immunotherapy therapy products in Greater China. Specifically, the companies intend to add up to two additional candidates from the 2seventy portfolio, one in solid tumor indications using T-cell receptor based technology and a second in autoimmune disease using a CAR T cell approach. JW Therapeutics has successfully progressed this candidate and is on track to initiate an investigator-initiated study in China by the end of 2023.

06:53 EDT BAE Systems secures additional GBP130M of new orders from UK MOD - BAE Systems has secured an additional GBP130M of new orders for the supply of munitions to the UK Ministry of Defence. The award follows the decision by the MOD to exercise the option to increase the supply contract announced in July from GBP280M to GBP410M. The full order with Defence Equipment and Support will be supplied via BAE Systems' facilities in Washington, Tyne and Wear, and Glascoed, South Wales. The overall contract will create more than 200 new highly skilled jobs in the North of England and South Wales, boosting the company's 1,200-strong UK munitions workforce.

06:52 EDT ANI Pharmaceuticals announces FDA approval and launch of Estradiol tablets - ANI Pharmaceuticals received FDA approval for the Abbreviated New Drug Application for Estradiol Tablets USP. ANI's Estradiol Tablets USP are the generic version of the Reference Listed Drug Estrace. The current annual U.S. market for Estradiol Tablets USP is approximately $40.9M.

06:42 EDT Hut 8 Mining mined 103 Bitcoin in August - Hut 8 Mining mined 103 Bitcoin in August. In total, 103 Bitcoin were generated, resulting in an average production rate of approximately 3.3 Bitcoin per day. No Bitcoin were sold during the month. Total balance of Bitcoin in reserve was 9,255 on August 31 - 7,158 of which was unencumbered. Installed ASIC hashrate capacity at our Alberta facilities was 2.6 EH/s at the end of the month Hut 8 produced 39.6 BTC/EH in August.

06:34 EDT Amazon.com, 1PointFive announce 10-year carbon removal credit purchase pact - 1PointFive, a carbon capture, utilization and sequestration company, announced that Amazon has agreed to purchase 250,000 metric tons of carbon dioxide removal credits over 10 years. The agreement furthers Direct Air Capture as a viable carbon removal solution to help organizations further their climate goals. The CDR credits for Amazon will be enabled by STRATOS, 1PointFive's first commercial-scale DAC plant, currently under construction in Texas. The plant is designed to capture up to 500,000 metric tons of CO2 annually when fully operational, making it the largest plant in the world, and a milestone in reaching climate relevant scale. 1PointFive is progressing the development of Carbon Engineering's Direct Air Capture technology, alongside other decarbonization solutions, at an industrial scale to help organizations achieve their net zero goals. Under the agreement with Amazon, the captured CO2 underlying the CDR credits will be stored in saline reservoirs that are not associated with oil and gas production.

06:31 EDT Affimed receives FDA fast track designation for AFM13/AlloNK combination - Affimed announced that the FDA has granted fast track designation to the combination of its innate cell engager AFM13 with AlloNK for the potential treatment of relapsed/refractory Hodgkin lymphoma. The combination treatment is entering Phase 2 development and will be investigated in Affimed's LuminICE-203 study, which received IND-clearance earlier this year; the study also includes an exploratory cohort of CD30-positive peripheral T-cell lymphoma patients.

06:07 EDT Banc of California appoints Debora Vrana as Chief Communications Officer - Banc of California announced that Debora Vrana has joined its wholly owned subsidiary, Banc of California, in the newly created role of Executive VP and Chief Communications Officer. She will also join the Bank's senior management committee and sit on the board of the Bank's philanthropic foundation. Samantha Haugh, SVP of Marketing for Banc of California, will continue to lead marketing and report to Vrana. In July, Banc of California and PacWest Bancorp announced a merger, including a $400M equity raise. Following the closing and anticipated asset sales, the combined bank is expected to have approximately $36.1B in assets and more than 70 branches in California, as well as branches in Colorado and North Carolina. The combined bank will be based in Los Angeles and operate under the Banc of California name. The deal is expected to close later this year or early next year. Vrana most recently served as Chief Communications Officer for Los Angeles-based City National Bank, which she joined in 2007. Previously, Vrana was a journalist at the Los Angeles Times for more than a decade.

06:03 EDT Walgreens, Pearl Health announce strategic partnership - Walgreens, a division of Walgreens Boots Alliance, and Pearl Health announced a partnership to accelerate the expansion of value-based care in collaboration with community-based primary care physicians. Pearl Health offers technology and insight solutions that empower clinical teams to provide holistic, personalized treatment necessary for value-based, quality-focused care. Walgreens will provide complementary services, including prescription fulfillment, medication adherence, immunizations, care gap closure and diagnostic testing. Walgreens will also work with providers to help patients discharged from the hospital transition to home.

06:02 EDT GigaCloud enters 'stalking horse' pact to buy assets of Noble House for $85M - GigaCloud Technology announced that it has entered into a definitive agreement as the stalking horse bidder to acquire substantially all of the assets of Noble House Home Furnishings, LLC and certain of its affiliates for $85M in connection with Noble House's Chapter 11 bankruptcy proceedings. Noble House is a leading distributor, manufacturer and retailer of an extensive selection of indoor and outdoor home furnishings. Noble House sells its portfolio of products through a diverse set of third-party channels, with leading positions at major retailers.

05:09 EDT State Street announces FX Connect collaboration with LoopFX - State Street announced that FX Connect, part of the GlobalLink suite of e-trading platforms, technology and workflow solution that provide capabilities, has entered into a collaboration with LoopFX, to make the LoopFX functionality available through FX Connect.

05:04 EDT Boeing announces SMBC order for 25 737-8s - Boeing and SMBC Aviation Capital announced the airplane lessor is ordering 25 737-8s. The new order increases SMBC's backlog to 81 737 MAX jets focused on the 737-8.